MedPath

Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study

Not Applicable
Terminated
Conditions
Acute Coronary Syndrome
Registration Number
NCT01172990
Lead Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Brief Summary

This is a pilot feasibility study to evaluate if patients with ST depression Acute Coronary Syndrome who are taken directly to the catheter laboratory for angiogram and angioplasty +/- stents will fare better that patients who are taken to the ward area and managed with drug therapy and stabilised for 24 hours before being taken to the catheter laboratory.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
108
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Ambulance recruitment rate per million of population (corrected for 9-5 recruitment)12 months (duration of study)
Secondary Outcome Measures
NameTimeMethod
The extent of myocardial damage will be evaluated using the area under the curve (AUC) for release of cardiac markers Creatinine Kinase Myocardial Band(CKMB) and troponinwithin 7 days
Recurrent non-fatal Myocardial Infarction (MI) (after 72 hours) at 30 daysat 30 days
Stroke at 30 daysat 30 days
Unplanned hospital stay (>72 hours)within 72 hours
Percentage of ambulance recruited patients, excluded from the trial ultimately manifesting a troponin positive ACS within 72 hourswithin 72 hours
Additional unplanned revascularisation at 30 days.at 30 days
Major bleeding30 days
Percentage of patients recruited by the ambulance services ultimately manifesting a troponin positive Acute Coronary Syndrome(ACS) within 72 hourswithin 72 hours
Death at 30 daysat 30 days

Trial Locations

Locations (1)

Royal Brompton And Harefield NHS Trust

🇬🇧

Harefield, Middlesex, United Kingdom

Royal Brompton And Harefield NHS Trust
🇬🇧Harefield, Middlesex, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.